Marzetti Emanuele, Calvani Riccardo, Tosato Matteo, Cesari Matteo, Di Bari Mauro, Cherubini Antonio, Collamati Agnese, D'Angelo Emanuela, Pahor Marco, Bernabei Roberto, Landi Francesco
Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart School of Medicine, Rome, Italy.
Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Aging Clin Exp Res. 2017 Feb;29(1):11-17. doi: 10.1007/s40520-016-0704-5. Epub 2017 Feb 2.
Sarcopenia, the age-dependent loss of muscle mass and function, is a common condition among older adults, and is associated with several adverse health outcomes. Owing to the impact of sarcopenia on quality of life, disability and mortality, a greater awareness is necessary in order to correctly identify the condition both in community and geriatric settings. Research on sarcopenia prevention and treatment is developing quickly, but many questions are still unanswered. The core of the sarcopenia condition involves quantitative and qualitative losses of skeletal muscle. These two dimensions should therefore be considered when designing and testing preventive and therapeutic interventions. The recently released operationalization of sarcopenia by the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project allows for the framing of an objective, standardized, and clinically relevant condition, which should facilitate its translation into the clinical arena as well as its adoption by public health and regulatory agencies. Such a conceptualization might eventually encourage key stakeholders to combine their efforts in approaching the sarcopenia condition. Bearing these considerations in mind, the "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" project has operationalized a specific condition, named physical frailty and sarcopenia (PF&S), characterized by the combination of low physical performance (based on the Short Physical Performance Battery) and low muscle mass (according to the FNIH cut-points). A randomized controlled trial will be conducted to evaluate the efficacy of a multi-component intervention for preventing mobility disability and other adverse health outcomes in older adults with PF&S.
肌肉减少症是一种与年龄相关的肌肉质量和功能丧失的病症，在老年人中很常见，并且与多种不良健康后果相关。由于肌肉减少症对生活质量、残疾和死亡率有影响，因此有必要提高认识，以便在社区和老年护理环境中正确识别这种病症。关于肌肉减少症预防和治疗的研究正在迅速发展，但许多问题仍未得到解答。肌肉减少症的核心涉及骨骼肌的定量和定性损失。因此，在设计和测试预防及治疗干预措施时应考虑这两个方面。美国国立卫生研究院基金会（FNIH）肌肉减少症项目最近发布的肌肉减少症操作化定义，使得能够构建一个客观、标准化且与临床相关的病症，这应有助于将其转化到临床领域，并被公共卫生和监管机构采用。这样的概念化最终可能会鼓励关键利益相关者共同努力应对肌肉减少症。考虑到这些因素，“老年人肌肉减少症与身体虚弱：多成分治疗策略”项目已经对一种特定病症进行了操作化定义，称为身体虚弱和肌肉减少症（PF&S），其特征是身体表现低下（基于简短身体表现测试电池）和肌肉质量低（根据FNIH切点）。将进行一项随机对照试验，以评估多成分干预措施对预防PF&S老年人行动能力残疾和其他不良健康后果的疗效。
